Nab-paclitaxel monotherapy as a treatment of patients with metastatic breast cancer in routine clinical practice
Aim: To compare treatment results with use of nab-paclitaxel in routine clinical practice with data obtained from clinical trials. Patients and Methods: A retrospective chart review of all 36 patients with metastatic breast cancer treated with nab-paclitaxel was performed. Nab-paclitaxel was given w...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
August 2013
|
| In: |
Anticancer research
Year: 2013, Jahrgang: 33, Heft: 8, Pages: 3407-3413 |
| ISSN: | 1791-7530 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://ar.iiarjournals.org/content/33/8/3407
|
| Verfasserangaben: | Julia Aigner, Frederik Marmé, Katharina Smetanay, Florian Schuetz, Dirk Jaeger and Andreas Schneeweiss |
| Zusammenfassung: | Aim: To compare treatment results with use of nab-paclitaxel in routine clinical practice with data obtained from clinical trials. Patients and Methods: A retrospective chart review of all 36 patients with metastatic breast cancer treated with nab-paclitaxel was performed. Nab-paclitaxel was given weekly and usually started at 150 mg/m2. Results: Thirteen (36.1%) patients received nab-paclitaxel as first-line, seven (19.4%) as second-line and 16 as third- or further line treatment. Overall, the response rate was 9.7%, disease control rate 64.5%, median progression-free survival 7.5 months and median overall survival 14.2 months. The most frequent non-hematological toxicities of grade 3 or more were fatigue (27.8%), dyspnea, rash and arthalgia (all 5.6%). Six (16.7%) patients developed peripheral neuropathy of grade 2 or more. Incidence of neutropenia grade 3 or more was 41.7% with no case of febrile neutropenia. Conclusion: According to our experience, weekly nab-paclitaxel is effective and tolerable, with results at least comparable to those from the prospective clinical trials. |
|---|---|
| Beschreibung: | Gesehen am 07.05.2021 |
| Beschreibung: | Online Resource |
| ISSN: | 1791-7530 |